The DOI matches its Crossref record.
Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin
Abstract
Study Objective. To compare the rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin administration. Design. Retrospective database analysis. Intervention. Evaluation of reported rates of torsades de pointes in patients who received these quinolones between January 1, 1996, and May 2, 2001. Measurements and Main Results. In the United States, 25 cases of torsades de pointes associated with these quinolones (ciprofloxacin 2, ofloxacin 2, levofloxacin 13, gatifloxacin 8, moxifloxacin 0) were identified. Ciprofloxacin was associated with a significantly lower rate of torsades de pointes (0.3 cases/10 million prescriptions, 95% confidence interval [CI] 0.0–1.1) than levofloxacin (5.4/10 million, 95% CI 2.9–9.3, p<0.001) or gatifloxacin (27/10 million, 95% CI 12–53, p<0.001 for comparison with ciprofloxacin or levofloxacin). When the analysis was limited to the first 16 months after initial U.S. approval of the agent, the rates for levofloxacin (16/10 million) and gatifloxacin (27/10 million) were similar (p>0.5). Conclusion. Levofloxacin should be administered with caution in patients with risk factors for QT prolongation. Gatifloxacin should be avoided in the same patient population, and the recommended dosage of 400 mg/day should not be exceeded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 12
- 10.1007/s002280050714 · DOI · Paper page
- 10.1592/phco.21.3.301.34206 · DOI
- Iannini PB, 2001, Risk of torsades de pointes with non‐cardiac drugs [letter], Br Med J, 322, 46
- 10.1592/phco.21.3.261.34200 · doi:10.1592/phco.21.3.261.34200
- 10.1592/phco.21.3.358.34205 · doi:10.1592/phco.21.3.358.34205
- 10.2165/00002018-199921050-00005 · DOI · Paper page
- 10.1093/jac/45.5.557 · doi:10.1093/jac/45.5.557
- Food and Drug Administration., 2000, Approved drug products with therapeutic equivalence evaluations, 20th ed
- Bayer Corporation., 2000, Cipro (ciprofloxacin) package insert
- Ortho‐McNeil Pharmaceutical., 2000, Levaquin (levofloxacin) package insert
- Bristol‐Myers Squibb Company., 2001, Tequin (gatifloxacin) package insert
- Bayer Corporation., 2001, Avelox (moxifloxacin) package insert
Cited by
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Gupta, A., Lawrence, A. T., Krishnan, K., Kavinsky, C. J., & Trohman, R. G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.040 · Cited by 362
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-360oc · Cited by 286
Hayes' Principles and Methods of Toxicology
(2014) · CRC Press eBooks · doi:10.1201/b17359 · Cited by 280
Guo, L., Abrams, R. M. C., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., & Kolaja, K. L. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr158 · Cited by 272
Metadata
- Authors
- Frothingham, R.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 21
- Issue
- 12
- Pages
- 1468-1472
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2048169841
- Cited by
- 208
- References
- 0
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin. https://app.cochat.ai/papers/10.1592/phco.21.20.1468.34482
- The paper
- Frothingham, R. (2001). Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.21.20.1468.34482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.